| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: LSBC |
| Security Type |
Common Stock |
| Lead Underwriter |
JP Morgan |
| Days In Registration |
126 |
| Date Filed |
6-Apr-2000 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Manufacture and wholesale plant-made pharmaceutical proteins and vaccines; provide research and development services |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
24.36M |
| CEO |
Robert L. Erwin |
| Number of Employees |
144 |
|
| Original Filing Information |
| US |
| Shares Filed |
3.57M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
3.57M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
750.0K |
| File Amount |
$74.97M |
| File Price Range |
$22.00 - $20.00 |
| File Mid Price |
$21.00 |
Current Filing Information
(Amended 9-Aug-2000) |
|
US |
|
Shares Filed |
4.5M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
4.5M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$58.5M |
| · % Change from Original |
-21.97 |
| File Price Range |
$14.00 - $12.00 |
| File Mid Price |
$13.00 |
|
